Hossein Borghaei, DO, MS, discusses selecting between single-agent versus combination therapies in lung cancer.
Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, professor, Department of Hematology/Oncology, co-director, Immune Monitoring Facility, Lung Cancer and Mesothelioma TRDG member, and Gloria and Edmund M. Dunn Chair in Thoracic Oncology, Fox Chase Cancer Center, discusses selecting between single-agent versus combination therapeutic approaches in lung cancer.
Single-agent therapies that are supported by clinical data are recommended for patients who are likely to achieve disease control with 1 drug, Borghaei says. Approved chemoimmunotherapy or immunotherapy combinations have demonstrated manageable safety profiles and should be considered in appropriate patients, Borghaei explains. Currently, PD-L1 expression can be used to inform which patients should receive combination regimens; however, additional biomarkers are needed, concludes Borghaei.